Literature DB >> 23939603

Postexposure prophylaxis for common infectious diseases.

Mazen S Bader1, David S McKinsey.   

Abstract

Postexposure prophylaxis (PEP) is effective in preventing illness after potential or documented exposure to a variety of microbial pathogens and in reducing the risk of secondary spread of infection. Guidelines have been published by the Centers for Disease Control and Prevention and the Advisory Committee on Immunization Practices for proper use of PEP for bloodborne pathogens, for microorganisms transmitted by either airborne or droplet spread or through direct contact, and for infections acquired after traumatic injuries. Depending on the type of exposure, different forms of PEP are available, including vaccines, immune globulins, antibiotics, and antiviral medications. Physicians should assess a patient's potential need for PEP based on several factors, including the type of exposure, the timing and severity of illness in the source patient, the exposed person's susceptibility to infectious diseases of concern, and the relative risks and benefits of the PEP regimen in an individual situation. Immunity to certain infectious diseases can be ensured with prior infection or vaccination, and by serologic testing in patients with a negative or uncertain history. PEP should be given to persons exposed to index cases of pertussis and invasive meningococcal infection regardless of immunization history, and should be given following rabies and tetanus exposure regardless of the length of delay. In general, PEP should be given as soon as possible following a high-risk exposure. Persons exposed to bloodborne pathogens should have baseline testing for human immunodeficiency virus, hepatitis B virus, and hepatitis C virus antibodies, and follow-up testing at six weeks, three months, and six months postexposure.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23939603

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  10 in total

1.  Boosting of post-exposure human T-cell and B-cell recall responses in vivo by Burkholderia pseudomallei-related proteins.

Authors:  Arnone Nithichanon; Louise J Gourlay; Gregory J Bancroft; Manabu Ato; Yoshimasa Takahashi; Ganjana Lertmemongkolchai
Journal:  Immunology       Date:  2017-02-09       Impact factor: 7.397

Review 2.  Emerging and reemerging neglected tropical diseases: a review of key characteristics, risk factors, and the policy and innovation environment.

Authors:  Tim K Mackey; Bryan A Liang; Raphael Cuomo; Ryan Hafen; Kimberly C Brouwer; Daniel E Lee
Journal:  Clin Microbiol Rev       Date:  2014-10       Impact factor: 26.132

3.  Development of a guinea pig inhalational anthrax model for evaluation of post-exposure prophylaxis efficacy of anthrax vaccines.

Authors:  Mark R Perry; Boris Ionin; Roy E Barnewall; Michelle L Vassar; Joshua J Reece; Sukjoon Park; Laurence Lemiale; Mario H Skiadopoulos; Jeffry D Shearer; Vladimir Savransky
Journal:  Vaccine       Date:  2020-02-03       Impact factor: 3.641

4.  Hematochezia: An Uncommon Presentation of Colonic Tuberculosis.

Authors:  Fares Ayoub; Vikas Khullar; Harry Powers; Angela Pham; Shehla Islam; Amitabh Suman
Journal:  Case Rep Gastrointest Med       Date:  2017-04-03

5.  Knowledge and Practices Related to Hepatitis B Infection among Dental and Oral Hygiene Students at a University in Pretoria.

Authors:  Thomas Khomotjo Madiba; Ntombizodwa Rosemary Nkambule; Tsholofelo Kungoane; Ahmed Bhayat
Journal:  J Int Soc Prev Community Dent       Date:  2018-05-17

6.  Ebola Virus Glycoprotein Induces an Innate Immune Response In vivo via TLR4.

Authors:  Chih-Yun Lai; Daniel P Strange; Teri Ann S Wong; Axel T Lehrer; Saguna Verma
Journal:  Front Microbiol       Date:  2017-08-17       Impact factor: 5.640

7.  Post-exposure prophylaxis (PEP) efficacy of rifampin, rifapentine, moxifloxacin, minocycline, and clarithromycin in a susceptible-subclinical model of leprosy.

Authors:  Shannon M Lenz; Jaymes H Collins; Nashone A Ray; Deanna A Hagge; Ramanuj Lahiri; Linda B Adams
Journal:  PLoS Negl Trop Dis       Date:  2020-09-16

8.  An enhanced regimen as post-exposure chemoprophylaxis for leprosy: PEP+.

Authors:  Liesbeth F Mieras; Anna T Taal; Wim H van Brakel; Emmanuelle Cambau; Paul R Saunderson; W Cairns S Smith; Cita Rosita S Prakoeswa; Linda Astari; David M Scollard; Dejair Caitano do Nascimento; Jacques Grosset; Hemanta K Kar; Shinzo Izumi; Laura Gillini; Marcos C L Virmond; Marieke G G Sturkenboom
Journal:  BMC Infect Dis       Date:  2018-10-05       Impact factor: 3.090

Review 9.  Occupational Health Update: Focus on Preventing the Acquisition of Infections with Pre-exposure Prophylaxis and Postexposure Prophylaxis.

Authors:  David J Weber; William A Rutala
Journal:  Infect Dis Clin North Am       Date:  2016-09       Impact factor: 5.982

Review 10.  Occupational Health Update: Approach to Evaluation of Health Care Personnel and Preexposure Prophylaxis.

Authors:  Erica S Shenoy; David J Weber
Journal:  Infect Dis Clin North Am       Date:  2021-09       Impact factor: 5.982

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.